Our Business

Takeda's journey expands and advances the translation of science into highly innovative medicines while maintaining our agility as a global, values-based, R&D-driven, biopharmaceutical leader.

Research & Development

We aspire to be a dynamic R&D organization that thinks, acts and interacts with the external world like no other. Our global team of researchers and scientists achieve this by harnessing cutting-edge science to push the boundaries of what is possible in order to bring transformative, life-changing therapies to patients worldwide. Hear some voices from our global R&D team and find out more about our therapeutic areas here.

Learn more

Our Products

We are committed to bringing better health and a brighter future to patients by translating science into highly innovative medicines. Our R&D efforts are focused on four therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.



Our manufacturing, engineering, quality assurance, and supply chain capabilities are continuously improved. We are seeking out innovation through digital science and partnerships. We conduct our business in a sustainable manner and foster a speak-up culture for people and product safety. You can find more information about our manufacturing here.

Learn more

Alliances & Partnerships

In order to achieve our vision of bringing better health and a brighter future to patients around the world, we seek partnerships to nurture the innovation we strive for. At Takeda, we’re looking for partners who believe our global reach, scientific expertise and clinical excellence can help them bring their vision to the market. You can find more information about partnering with Takeda here.


Access to Medicines

Takeda believes access to healthcare and medicines should be universal. However, across the world, many people lack access to the services and treatment they need. We are expanding on our existing commitments to enhance global health so that patients in evolving healthcare systems can have access to our innovative and potentially life-saving medicines, even if their ability to pay for the full cost of treatment is limited. Details on how we do this through our Access to Medicines strategy can be found here.



T-CiRA is a joint research program by the Center for iPS Cell Research and Application (CiRA), Kyoto University and Takeda Pharmaceutical Company Limited. Over a 10-year period and under the direction of CiRA, this joint program will conduct research to develop clinical applications of iPS cells. Find out more about this innovative program here.

Learn more